Liquidia Corporation — Third Quarter 2026 Earnings Summary

Liquidia Corporation reported a net loss of $236.3 million for the third quarter of 2026, a figure that includes a $389.7 million charge for a global litigation settlement with United Therapeutics. Despite the settlement charge, the company achieved net product sales of $222.7 million for YUTREPIA, marking a 31% increase from the previous quarter and securing continuity of care for all patients. The company's cash and cash equivalents rose to $396.1 million prior to settlement payments, while non-GAAP adjusted EBITDA reached $140.5 million for the fifth consecutive quarter. Additionally, Liquidia received Fast Track designation from the FDA for YUTREPIA to treat systemic sclerosis-associated Raynaud's phenomenon and initiated the RE-WARM Phase 2 study for this indication.